Novel GLP-1 receptor agonists for diabetes

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Neuroprotective properties of GLP-1: theoretical and practical applications

(2011) Jens Juul Holst et al.   CURRENT MEDICAL RESEARCH AND OPINION

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

(2011) C. Wysham et al.   DIABETIC MEDICINE

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

(2010) Eduard Montanya et al.   CLINICAL THERAPEUTICS

Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?

(2010) Mikkel Christensen et al.   Current Diabetes Reports

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

(2010) B. W. Bode et al.   DIABETES OBESITY & METABOLISM

The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review

(2010) Satish K. Garg   Diabetes Technology & Therapeutics

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2

(2010) R. Ratner et al.   DIABETIC MEDICINE

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

(2010) Erin L St Onge et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Exenatide and weight loss

(2010) David P. Bradley et al.   NUTRITION

Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus

(2009) Joshua J Neumiller et al.   ANNALS OF PHARMACOTHERAPY

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes

(2009) Tina Vilsbøll et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

(2009) Sten Madsbad   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

(2009) David J Grieve et al.   BRITISH JOURNAL OF PHARMACOLOGY

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

(2009) J. A. DAVIDSON   CLEVELAND CLINIC JOURNAL OF MEDICINE

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

(2009) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of Exenatide Alone and in Combination With Daclizumab on  -Cell Function in Long-Standing Type 1 Diabetes

(2009) K. I. Rother et al.   DIABETES CARE

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

(2009) M. A. Nauck et al.   DIABETES CARE

Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes

(2009) C. Kapitza et al.   DIABETIC MEDICINE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Meal-Anticipatory Glucagon-Like Peptide-1 Secretion in Rats

(2009) Torsten P. Vahl et al.   ENDOCRINOLOGY

Exenatide once weekly for the treatment of type 2 diabetes

(2009) James Malone et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue

(2009) Kjetil Retterstøl   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

(2009)   LANCET

Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus

(2009) Scott R Drab   PHARMACOTHERAPY

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies

(2008) A. Penfornis et al.   DIABETES & METABOLISM

The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions

(2008) J. Girard   DIABETES & METABOLISM

GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival

(2008) J. Buteau   DIABETES & METABOLISM

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

GLP-1: physiological effects and potential therapeutic applications

(2008) Kasper Aaboe et al.   DIABETES OBESITY & METABOLISM

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

(2008) Nasser Mikhail   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Nutritional regulation of glucagon-like peptide-1 secretion

(2008) Gwen Tolhurst et al.   JOURNAL OF PHYSIOLOGY-LONDON

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

Glucagon-like peptide-1, glucose homeostasis and diabetes

(2008) Jens J. Holst et al.   TRENDS IN MOLECULAR MEDICINE